Show
Sort by
-
- Journal Article
- A1
- open access
Prognostic discrimination based on the EUTOS long-term survival score within the International Registry for Chronic Myeloid Leukemia in children and adolescents
-
Additional cytogenetic abnormalities and variant t(9;22) at the diagnosis of childhood chronic myeloid leukemia : the experience of the International Registry for Chronic Myeloid Leukemia in Children and Adolescents
-
Analysis of a global registration trial of the efficacy and safety of CTL019 in pediatric and young adults with relapsed/refractory acute lymphoblastic leukemia (ALL)
-
Prognostic discrimination of children and adolescents with chronic myeloid leukemia based on the EUTOS Long Term Survival (ELTS) score
-
Phase I study to evaluate dose, safety and tolerability of the polo-like kinase inhibitor Volasertib in paediatric patients with acute leukaemia and advanced solid tumours
-
Childhood acute lymphoblastic leukemia : progress through collaboration
-
Phase II study on bortezomib (BTZ) in multiple relapsed or refractory pediatric acute lymphoblastic leukemia (rALL) : high response rate with a modestly intensive regimen including BTZ, not related to pharmacokinetics
-
Switch to subsequent line of treatment in children and adolescents with chronic myeloid leukemia (CML) treated with imatinib : experience of the International Registry for Chronic Myeloid Leukemia in Children and Adolescents (I-CML-Ped study)
-
Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia
-
Results of a feasibility and phase II study on bortezomib (BTZ) in pediatric multiply relapsed of refractory acute lymphoblastic leukemia: complete hematological responses with a modestly intensive regimen including BTZ